Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for antibody-drug conjugates (ADCs) that combines the ADC linker (Acetylene-linker-Val-Cit-PABC) with the potent tubulin inhibitor MMAE.

Mal-(CH2)5-Val-Cit-PAB-Eribulin is a potent antitumor ADC drug-linker conjugate that utilizes Eribulin, an anti-microtubule agent, connected through the Mal-(CH2)5-Val-Cit-PAB linker.

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

DBCO-PEG4-VC-PAB-MMAE, an ADC linker comprising DBCO-PEG4-VC-PAB coupled with the tubulin polymerization inhibitor MMAE, serves as a key component in the formulation of antibody-drug conjugates (ADCs). MMAE, a synthetic derivative of dolastatin 10, inhibits tubulin polymerization, acting as a potent mitotic inhibitor.

Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan是一个ADC药物-linker偶联物，包含Exatecan和linker。该化合物主要用于ADC合成与癌症研究。

Glucocorticoid receptor agonist-2 Ala-Ala-Mal（化合物79）是ABBV-3373的活性对照，可用于合成抗炎ADC分子。

SC239为一种2-氨基苯基半紫杉烷类活性分子连接剂，具有可裂解特性。该化合物适用于抗体药物偶联物（ADC）的活性分子连接。

MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan是一个构成抗体药物偶联物(ADC)活性部分的化合物，由ADC连接子(MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic)与DNA拓扑异构酶I抑制剂Exatecan通过化学键合形成。此合成ADC主要应用于癌症研究领域。

MC-VA-PABC-MMAE是一种ADC(Linker为peptide MC-VA-PABC)的活性分子，由Linker与高效微管蛋白抑制剂MMAE通过偶联反应形成。